This chapter outlines the important and common late-onset, long-term endocrine disorders that occur as a consequence of cancer therapy in survivors: bone metabolism disorders, metabolic (i.e., glucose and lipid) disorders, thyroid neoplasia and dysfunction, hypothalamic-pituitary dysfunction, adrenal dysfunction, and gonadal system disorders. Strategies for evaluating and managing these effects are included.
KeywordsBone Mineral Density Bone Loss Cancer Survivor Androgen Deprivation Therapy Adrenal Insufficiency
- Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–1810.PubMedCrossRefGoogle Scholar
- Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119–127.PubMedCrossRefGoogle Scholar
- Ezdinli EZ, Stutzman L. Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA 1965;191:444–450.Google Scholar
- Kusuki M, Iguchi H, Nakamura A, et al. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer. Acta Otolaryngol Suppl 2004:74–77.Google Scholar
- Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 2009;5:515–519.Google Scholar
- Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh) 1993;129:31–38.Google Scholar